
Chinese biopharmaceutical company founded in December 2004 in Hangzhou, Zhejiang with 40 million yuan of registered capital, designated a national high-tech enterprise and a leading Zhejiang developer and maker of microecological preparations. It joined China Grand Pharmaceutical Group as a wholly owned subsidiary in 2013 and invests heavily each year in microecological and large-molecule drug development, growing revenue at more than thirty percent a year. Its flagship product is a four-strain live Bifidobacterium tablet covered by its own patents, the first Chinese national new drug to combine four bacterial strains from different genera.
查看公司简介
留下您的评分